Personalized medicine

Beyond Medtech: Healthcare+ Expo Taiwan Sets New Stage for Global Innovation in Future AI Healthcare

Retrieved on: 
Friday, December 1, 2023

The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape of AI healthcare on a global scale.

Key Points: 
  • The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape of AI healthcare on a global scale.
  • View the full release here: https://www.businesswire.com/news/home/20231201062013/en/
    Expand businesses into growing markets in the APAC region with Healthcare+ Expo Taiwan.
  • This proficiency positions Taiwan as a key player in driving substantial computing power, establishing it as an indispensable global collaborator in the realm of AI healthcare.
  • The Healthcare+ Expo 2024 is scheduled for December 5 to 8, 2024, and will continue to serve as a catalyst for transformative advancements and collaborative breakthroughs in the ever-evolving landscape of AI healthcare.

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on: 
Friday, November 17, 2023

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points: 
  • Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
  • (Photo: Business Wire)
    Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
  • Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
  • "We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.

Nanomaterials in Personalized Medicine Global Markets Report 2023: Trends and Data from 2020-2023 and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023

The global market for nanomaterials in personalized medicine was valued at $312.8 billion in 2022.

Key Points: 
  • The global market for nanomaterials in personalized medicine was valued at $312.8 billion in 2022.
  • This report will highlight the current and future market potential of nanomaterials in personalized medicine, with a detailed analysis of the competitive environment.
  • The increasing prevalence of chronic diseases is boosting the already growing demand for global nanomaterials in the personalized medicine market.
  • Major players in the nanomaterials in personalized medicine markets include Bristol-Myers Squibb Co., Eisai Co. Ltd., Gilead Sciences, Ipsen SA, and many others.

Expanding the Reach of Care for Cancer and Other Disease States: BAMF Health and GE HealthCare collaborate to enable sustainable and scalable solutions for growth in Theranostics

Retrieved on: 
Monday, November 13, 2023

As demand for Theranostic care increases, GE HealthCare and BAMF Health are excited to announce a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services.

Key Points: 
  • As demand for Theranostic care increases, GE HealthCare and BAMF Health are excited to announce a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services.
  • The goal of the collaboration is to ensure an agile go-to-market approach to enhance the adoption of Theranostics solutions in the U.S.
  • The arrangement supports a shared interest in better patient outcomes made possible through advanced diagnostics and radiotherapeutics.
  • The collaboration between GE HealthCare and BAMF Health will leverage both partners’ deep understanding of the complexities of delivering Theranostic care to establish a framework to support the scalable infrastructure and clinical solutions for expanded adoption of precision care.

Cohen Veterans Bioscience Announces Executive Leadership Changes Magali Haas, MD/PhD, Founder, CEO & President will step down after 12 Years at CVB Helm and assume new Strategic Role; Peter Hoehn, JD, Appointed CEO, Nicole Harmon, PhD, to Assume Role of P

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- Cohen Veterans Bioscience (CVB) today announces long-planned executive changes to the organization.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- Cohen Veterans Bioscience (CVB) today announces long-planned executive changes to the organization.
  • Magali Haas, MD, PhD, Founder, CEO & President will be transitioning into new International Strategic leadership roles as well as serving as Senior Advisor to the new CEO.
  • Peter Hoehn, JD, Executive Vice President, Marketing Strategy, Development, and Impact is appointed Chief Executive Officer (CEO); Nicole Harmon, PhD, Chief Operating Officer, is designated President.
  • Dr. Haas will focus on leading the newly launched TBI Action Alliance and the International Brain Health Initiative.

THE ACADEMY OF ONCOLOGY NURSE & PATIENT NAVIGATOR'S (AONN+) PRECISION MEDICINE TOOLKIT NAMED ONE OF THE MOST INTERESTING INNOVATIONS OF 2023 BY PM360

Retrieved on: 
Thursday, December 14, 2023

AONN+'s Precision Medicine Toolkit was included within the Life Sciences category.

Key Points: 
  • AONN+'s Precision Medicine Toolkit was included within the Life Sciences category.
  • Precision medicine is a rapidly evolving area of cancer care, and oncology nurse and patient navigators are often called upon to support newly diagnosed patients receiving these emerging treatments and the genetic and genomic tests that accompany them.
  • AONN +, along with Pfizer Oncology, developed this toolkit to increase oncology navigators' precision medicine knowledge base and empower them to play an active role when working with these patients.
  • "This toolkit has been very well received by oncology navigators around the nation," says Ms Dean.

Precision Medicine Group Releases Its Inaugural Annual Environmental, Social and Governance Report

Retrieved on: 
Thursday, December 14, 2023

BETHESDA, Md., Dec. 14, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, has published its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • BETHESDA, Md., Dec. 14, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, has published its 2023 Environmental, Social and Governance (ESG) Report.
  • This inaugural annual report provides a detailed account of the organization's priorities, which include a focus on doing better for people within the PMG organization and the broader community, including environmental preservation, social well-being and ethical leadership.
  • "At PMG, our mission is to accelerate development and access to breakthrough therapies that improve the lives of patients in need," said Stacey Hanna, General Counsel and Chief Compliance Officer of Precision Medicine Group.
  • In 2023, PMG initiated various energy efficiency projects and standards across the company's facilities and measured associated emissions reductions from the baseline.

Seattle Hub for Synthetic Biology launched by Allen Institute, Chan Zuckerberg Initiative, and the University of Washington will turn cells into recording devices to unlock secrets of disease

Retrieved on: 
Thursday, December 7, 2023

SEATTLE, Dec. 7, 2023 /PRNewswire/ -- The Allen Institute, the Chan Zuckerberg Initiative (CZI), and the University of Washington (UW) today announced the launch of the Seattle Hub for Synthetic Biology: a landmark collaboration that will build new technologies to record the history of cells over time. These technologies will help researchers crack the code and understand not just end point measurements of cells and genes in health and disease but the dynamics of their trajectories over time. The Seattle Hub for Synthetic Biology brings together the best of large-scale science and philanthropy with proven academic power to develop, refine, and share this paradigm-shifting single-cell technology. Led by UW Medicine researchers Jay Shendure, M.D., Ph.D., Marion Pepper, Ph.D., Cole Trapnell, Ph.D., and Jesse Gray, Ph.D., the Seattle Hub for Synthetic Biology will build on technology pioneered at the Allen Discovery Center for Cell Lineage Tracing and UW Medicine's Brotman Baty Institute for Precision Medicine to reimagine living cells and genomes as devices for recording complex biological information over time.

Key Points: 
  • These technologies will help researchers crack the code and understand not just end point measurements of cells and genes in health and disease but the dynamics of their trajectories over time.
  • The Seattle Hub for Synthetic Biology brings together the best of large-scale science and philanthropy with proven academic power to develop, refine, and share this paradigm-shifting single-cell technology.
  • This new paradigm has the potential to revolutionize how scientists study the role of cells and genes in human health.
  • "Our shared values, paired with our complimentary perspectives and strengths, are a recipe for success, and I can't wait to see what this team will accomplish together."

GenomOncology's Data Solution IgniteIQ to Advance Natural Language Processing Pipeline for National Cancer Center

Retrieved on: 
Tuesday, November 28, 2023

CLEVELAND, Nov. 28, 2023 /PRNewswire/ -- GenomOncology announced today that City of Hope, one of the largest cancer research and treatment organizations in the United States, will advance City of Hope's natural language processing (NLP) pipeline using HopeIQ, a City of Hope data enablement solution powered by GenomOncology's igniteIQ.

Key Points: 
  • CLEVELAND, Nov. 28, 2023 /PRNewswire/ -- GenomOncology announced today that City of Hope, one of the largest cancer research and treatment organizations in the United States, will advance City of Hope's natural language processing (NLP) pipeline using HopeIQ, a City of Hope data enablement solution powered by GenomOncology's igniteIQ.
  • To support the broader integration of this real-world data into POSEIDON, GenomOncology provided its HopeIQ augmented NLP data curation solution alongside expert data abstraction services.
  • The state-of-the-art technology utilizes the expert-in-loop model, biomarker normalization, and structure detection to streamline natural language processing, as well as ensure accuracy for data analysis.
  • Their focused and automated data enablement solution, igniteIQ, simplifies the extraction of medical information from various documents and images, while ensuring the privacy and security of patient data as per legal standards.

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Retrieved on: 
Tuesday, November 28, 2023

Combining genetic data and critical biomarkers, means targeted precision therapies based on patients' genetic profiles will be more readily available.

Key Points: 
  • Combining genetic data and critical biomarkers, means targeted precision therapies based on patients' genetic profiles will be more readily available.
  • BioReference and Prognos collaborate to offer healthcare providers and researchers unique RWD solutions.
  • Prognos is accelerating the development and delivery of innovative therapies and provides an unparalleled collection of health records on more than 325 million de-identified patient health records.
  • "We are thrilled to collaborate with BioReference Health, a leader in genomic data and laboratory analytics," added Sundeep Bhan, CEO of Prognos Health.